Organic transformations mediated
by visible light have
gained popularity
in recent years as they are green, renewable, inexpensive, and clean
and yield excellent products. The present study describes cyclo-condensation
of 2-methylthiazole-4-carbothioamide with differently substituted
α-bromo-1,3-diketones achieved by utilizing a white light-emitting
diode (LED) (9W) to accomplish the regioselective synthesis of novel
5-aroyl/hetaroyl-2′,4-dimethyl-2,4′-bithiazole derivatives
as DNA/bovine serum albumin (BSA)-targeting agents. The structure
characterization of the exact regioisomer was achieved unequivocally
by heteronuclear two-dimensional nuclear magnetic resonance (2D-NMR)
spectroscopy [1H–13C] HMBC; [1H–13C] HMQC; and [1H–15N] HMBC. In silico toxicity studies indicated that the synthesized
compounds exhibit low toxicity risks and adhere to the rules of oral
bioavailability without any exception. Computational molecular modeling
of the bithiazole derivatives with the dodecamer sequence of the DNA
duplex and BSA identified 5-(4-chlorobenzoyl)-2′,4-dimethyl-2,4′-bithiazole 7g as the most suitable derivative that can interact effectively
with these biomolecules. Furthermore, theoretical results concurred
with the ex vivo binding mode of the 7g with calf thymus
DNA (ct-DNA) and BSA through a variety of spectroscopic techniques,
viz., ultraviolet–visible (UV–visible), circular dichroism
(CD), steady-state fluorescence, and competitive displacement assay,
along with viscosity measurements.